PCVX — Vaxcyte, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1649094 ·
Last close
$56.21
Market Cap
$8.36B
52W High
$65.00
52W Low
$31.89
ADV30
1,199,267
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -302,777,000 | -284,302,000 | 3,138,154,000 | 183,190,000 | 380,212,000 |
| Mar 2026 | 0 | — | -345,850,000 | -320,622,000 | 3,348,308,000 | 260,843,000 | 352,294,000 |
| Dec 2025 | 0 | — | -274,283,000 | -246,507,000 | 3,002,717,000 | 173,959,000 | 317,207,000 |
| Sep 2025 | 0 | — | -242,380,000 | -212,830,000 | 3,171,600,000 | 281,080,000 | 278,718,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-881,233,000
Investing CF
$150,604,000
Financing CF
$606,021,000
CapEx
$-39,835,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-7.05
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,759,871,000
Inventory
—
Receivables
—
ST Investments
$1,303,648,000
EBIT TTM
$-1,165,290,000
Pretax Income TTM
$-1,064,261,000
Interest Exp TTM
—
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -923,675,000 | -766,628,000 | 3,002,717,000 | 317,207,000 | 2,685,510,000 | -655,577,000 |
| Dec 2024 | 0 | -569,546,000 | -463,927,000 | 3,511,318,000 | 205,499,000 | 3,305,819,000 | -452,627,000 |
| Dec 2023 | 0 | -393,041,000 | -402,266,000 | 1,407,917,000 | 167,449,000 | 1,240,468,000 | -296,790,000 |
| Dec 2022 | 0 | -209,261,000 | -223,485,000 | 1,006,178,000 | 52,565,000 | 953,613,000 | -170,597,000 |
TTM Snapshot
Revenues TTM
$79,487,000
NetIncome TTM
$-336,506,000
OpCashFlow TTM
$0
Assets (Latest)
$3,002,717,000
Forward EPS
$-7.22
Max Pain — expiry 2026-10-16
max pain strike: $55.00 · spot: $57.08 · call oi: 13,762 · put oi: 14,816
Expected Move to 2026-10-16:
±$12.35
(21.64%) —
implied range
$44.73 –
$69.43
· ATM straddle on $55.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IBRX | ImmunityBio, Inc. | $8.95B | $8.44 | — |
| QGEN | QIAGEN N.V. | $9.12B | $44.18 | — |
| KYMR | Kymera Therapeutics, Inc. | $9.21B | $111.95 | — |
| IMVT | Immunovant, Inc. | $6.88B | $33.30 | — |
| KRYS | Krystal Biotech, Inc. | $10.24B | $345.82 | — |
News headlines (Yahoo Finance, 1h cache)
Vaxcyte VAX-31 Positioned to Validate Broad Coverage, BofA Says
2026-09-28 15:38 · Yahoo
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte
2026-09-23 12:37 · Yahoo
Vaxcyte (PCVX) Dropped, So What Is Driving Attention Now?
2026-09-21 15:12 · Yahoo
Vaxcyte (PCVX) Brings In Pharma Veterans As Its Big Test Nears
2026-09-17 04:20 · Yahoo
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing
2026-09-08 10:11 · Yahoo
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know
2026-09-08 09:57 · Yahoo
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm
2026-09-08 09:44 · Yahoo
The Next Year Will Define Vaxcyte’s (PCVX) Vaccine Gamble
2026-09-06 14:09 · Yahoo
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
2026-09-03 20:05 · Yahoo
Vaxcyte to Participate in Upcoming Investor Conferences
2026-08-27 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.